Haystack Bio and Intertrust Genecloud Partner for Precision Medicine Analytics

SUNNYVALE, Calif., May 18, 2016 — Intertrust Technologies Corporation and Haystack Bio, a pioneer in immuno-technologies, today announced that Haystack will use Intertrust’s Genecloud platform for trusted healthcare analytics. Under the partnership, Haystack Bio will use Genecloud to securely store, analyze and share data collected from Haystack Bio’s advanced single-cell discovery platform.

Immunotherapies and genomic medicines are transforming how we treat cancer, infectious disease, and autoimmune diseases. Drugs and vaccines that harness the immune system are rapidly emerging as the foundation for the next generation of precision and cellular medicines. Founded by leaders in the field of single-cell genomics from MIT and Berkeley, Haystack Bio has developed a revolutionary analysis platform that incorporates breakthrough cell imaging, genomics and advanced bioinformatics. Building on this platform, Haystack is creating a unique immunology knowledge-base and discovery engine that is yielding novel insights to drive the next generation of therapies.

Genecloud is a distributed Big Data platform for trusted storage and analysis of genomic and other health information. Intertrust built Genecloud to enable collaboration within and between institutions to address issues such as genomic privacy by allowing users to interact with sensitive data only through secured computer programs —trusted analytics — that are governed by stakeholder policies. Genecloud ensures that all customer data is persistently protected and accessible only to those with demonstrable rights to interact with it. Sophisticated auditing mechanisms guarantee that all accesses are logged to support customer compliance efforts.

“Haystack Bio’s platform will be used by biopharma partners and research institutions around the world.  We believe that Genecloud is the best way to store, analyze and collaborate around data, maximizing productivity while protecting privacy. Data governance is essential for genomics, and nobody addresses this challenge as deeply or as systematically as Genecloud,” said Jim Flanigon, CEO of Haystack Bio.

“We are very excited to partner with Haystack Bio in their mission to bring cutting edge single-cell analysis into mainstream drug development,” said Knox Carey, vice president of technology initiatives at Intertrust and general manager of Genecloud. “Our partnership will allow Haystack and its customers to collaborate securely and develop novel insights with firm assurances that their data and intellectual property are absolutely protected.”

 

###

 

About Intertrust

Intertrust provides trusted computing products and services to leading global corporations – from mobile and CE manufacturers and service providers to enterprise software platform companies. These products include the world’s leading digital rights management, software tamper resistance and privacy-driven data platforms for media and entertainment, ad tech, healthcare and IoT.

Founded in 1990, Intertrust is based in Silicon Valley, with regional offices in London and Beijing. The Company has a legacy of invention, and its fundamental contributions in the areas of computer security and digital trust are globally recognized. Intertrust holds hundreds of patents that are key to Internet security, trust and privacy management components of operating systems, trusted mobile code and networked operating environments, web services and cloud computing. Additional information is available atintertrust.com. Follow Intertrust on Twitter or LinkedIn.

About Haystack Bio

HaystackBio is an immuno-discovery and engineering company for precision cellular medicines. We employ a fully integrated and proprietary single-cell platform that includes breakthrough single-cell profiling, cloud-based data processing and analytics. The result is an immuno-knowledgebase and discovery engine that uniquely enables us to generate novel insights from complex samples—needles in haystacks—and then use this information to help stratify and engineer more durable immune medicines. Additional information is available at haystackbio.com.

Media Contacts

Robin Buckley
DC2SFGroup LLC
703.533.9805 or 703.201.3524 (mobile)
robin@dc2sfgroup.com

Leigh Anne Varney
Varney Business Communication
415.713.0713
la@varneybusiness.com